United Therapeutics
UTHR
366 hedge funds and large institutions have $9.02B invested in United Therapeutics in 2015 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 122 increasing their positions, 145 reducing their positions, and 25 closing their positions.
144% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 25
69% more call options, than puts
Call options by funds: $85.1M | Put options by funds: $50.3M
26% more capital invested
Capital invested by funds: $7.13B → $9.02B (+$1.89B)
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
10% more funds holding
Funds holding: 334 → 366 (+32)
16% less repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 145
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$124M |
| 2 |
FAM
Fred Alger Management
New York
|
+$84.9M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$67M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.6M |
| 5 |
PC
PointState Capital
New York
|
+$59.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$102M |
| 2 |
Millennium Management
New York
|
-$91M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$82.6M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$42.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$30.4M |
UTHR Hedge Fund Activity: Q1 2015 in Review
366 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2015, worth a combined $9.02B — up 26% from $7.13B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new UTHR positions and 25 closed out — a net gain of 36 holders — while 122 added to existing stakes and 145 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $124M. The largest seller was Citadel Advisors, cutting an estimated $102M.
- 366 institutional investors held United Therapeutics (UTHR) as of Q1 2015, up from 334 in Q4 2014.
- Funds reported $9.02B of United Therapeutics stock for Q1 2015, up 26% quarter-over-quarter.
- 61 funds opened new United Therapeutics positions in Q1 2015 and 25 closed out, a net change of +36 holders.
- The largest United Therapeutics buyer in Q1 2015 was Westfield Capital Management, an estimated $124M added.
- The largest United Therapeutics seller in Q1 2015 was Citadel Advisors, an estimated $102M sold.
Based on aggregated 13F filings for Q1 2015.